Document is current
Any future updates will be listed below
-
Authors
Socié, Gérard https://orcid.org/0000-0002-2114-7533
Barba, Pere
Barlev, Arie https://orcid.org/0000-0002-2999-7647
Sanz, Jaime https://orcid.org/0000-0001-6934-4619
García-Cadenas, Irene https://orcid.org/0000-0002-2994-9055
Chevallier, Patrice https://orcid.org/0000-0003-3142-5581
Fagioli, Franca https://orcid.org/0000-0002-9257-900X
Guzman-Becerra, Norma
Kumar, Deepali https://orcid.org/0000-0003-1961-0477
Ljungman, Per https://orcid.org/0000-0002-8281-3245
Pigneux, Arnaud
Sadetsky, Natalia
Yáñez San Segundo, Lucrecia
Shadman, Mazyar
Storek, Jan https://orcid.org/0000-0002-7884-9122
Thirumalai, Dhanalakshmi
Xing, Baodong
Mohty, Mohamad https://orcid.org/0000-0002-7264-808X
-
Funding
Funding for this research was provided by:
Atara Biotherapeutics
- License Information
-
More Information
Article History
Received: 19 July 2023
Revised: 27 September 2023
Accepted: 11 October 2023
First Online: 21 October 2023
Competing interests
: PB has received compensation as a member of a scientific advisory boards for Allogene, Amgen, B.M.S., Kite/Gilead, Incyte, Novartis and Pierre Fabre, and consulting fees from Jazz Pharmaceuticals, Milteny Biomed., Nektar and Novartis. DK has received research grants from Atara Biotherapeutics and GSK, and consulting fees from GSK, Merck, Takeda, Roche and Allovir. LYSS has received compensation for consulting/advisory roles for Abbvie, AstraZeneca, Beigene, BMS and Janssen in the past 2 years. AB, NG and BX are employees and shareholders of Atara Biotherapeutics. NS and DT were employees and shareholders of Atara Biotherapeutics at the time of the study. The other authors declare no competing interests.
